Literature DB >> 2083135

[Magnetic resonance imaging in optic nerve lesions with multiple sclerosis].

S Kojima1, K Hirayama, Y Kakisu, E Adachi.   

Abstract

Magnetic resonance imaging (MRI) of the optic nerves was performed in 10 patients with multiple sclerosis (MS) using short inversion time inversion recovery (STIR) pulse sequences, and the results were compared with the visual evoked potentials (VEP). The 10 patients had optic neuritis in the chronic or remitting phase together with additional symptoms or signs allowing a diagnosis of clinically definite or probable MS. Sixteen optic nerves were clinically affected and 4 were unaffected. MRI was performed using a 0.5 tesla superconducting unit, and multiple continuous 5 mm coronal and axial STIR images were obtained. A lesion was judged to be present if a focal or diffuse area of increased signal intensity was detected in the optic nerve. In VEP, a delay in peak latency or no P 100 component was judged to be abnormal. With regard to the clinically affected optic nerves, MRI revealed a region of increased signal intensity in 14/16 (88%) and the VEP was abnormal in 16/16 (100%). In the clinically unaffected optic nerves, MRI revealed an increased signal intensity in 2/4 (50%). One of these nerves had an abnormal VEP and the other had a VEP latency at the upper limit of normal. The VEP was abnormal in 1/4 (25%). In the clinically affected optic nerves, the degree of loss of visual acuity was not associated with the longitudinal extent of the lesions shown by MRI. The mean length was 17.5 mm in optic nerves with a slight disturbance of visual acuity and 15.0 mm in nerves with severe visual loss.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2083135

Source DB:  PubMed          Journal:  No To Shinkei        ISSN: 0006-8969


  1 in total

1.  Optic nerve injury demonstrated by MRI with STIR sequences.

Authors:  S Takehara; T Tanaka; K Uemura; Y Shinohara; T Yamamoto; T Tokuyama; A Satoh
Journal:  Neuroradiology       Date:  1994-10       Impact factor: 2.804

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.